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106 Poster Session IIBackground: The HCT-CI is a comorbidity score adapted to
hematopoietic cell transplantation, which has identified 3 risk
groups with increased non-relapse mortality (NRM) and lower
overall survival (OS) (Blood 2005;106:2912). We determined the
HCT-CI score in a cohort of patients who underwent myeloabla-
tive MUD transplantation in an single institution trial. Methods:
The analysis included all patients undergoing MUD transplant
from 1996–2006 who received a 3-drug GVHD prophylaxis regi-
men. Comorbidities were obtained by retrospective chart review
and scored according to the HCT-CI score. Results: 150 patients
(median age 40) were included, with 38% low-, 34% intermediate-
and 28% high-risk disease, per CIBMTR classification. Diagnoses
included acute leukemia in 50%, MDS in 12%, CML in 15%,
and lymphoma in 18%. Conditioning regimens were Cy-TBI in
64% and Bu-Cy in 21%. HCT-CI scores of 0, 1–2 or $3 were
found in 17%, 30% and 53% of patients. The majority of comor-
bidities were pulmonary (72%). Day 100 and 5-year OS were 82.7
and 33%, with a 23% and 50.4% cumulative incidence of NRM.
Five year relapse-related mortality was 15.8%. No statistically
significant differences in NRM or OS were detected using the
HCT-CI grouping of 0, 1–2 and $3. Unadjusted hazard ratio
(HR) for inferior survival were 0.9 (CI 0.47–1.85, P 5 .79) and
1.65 (CI 0.885–3.090, P5 .11) for scores 1–2 and$3, respectively.
We determined an alternate prognostic model based on 2 groups.
Statistical modeling separated patients with a score of 0–3 (n 5
97, 64%) and $4 (n 5 53, 35.6%), with a 3 month and 5 year OS
of 84% and 45% versus 52% and 10%, respectively (P\ .0001).
Cumulative incidence of day 100 and 5-year NRM was 16% and
38% versus 43% and 73%, respectively. UnadjustedHR for inferior
survival was 2.77 (CI 1.816–4.225, P\ .0001) for a score of$4. By
multivariate analysis, only the HCT-CI score (P\ .0001) and the
disease risk per CIBMTR (P 5 .0058) were predictive of OS and
NRM, but not age, CMV status, sex- or HLA-mismatch, or regi-
men. Conclusions: Although the HCT-CI score was predictive
of NRM and OS in this high-risk cohort, we were unable to detect
statistically significant differences between the 3 risk groups defined
in the original score. A modified 2-group scoring system of 0–3 and
$4, respectively, identified a low-risk and a high-risk group. This
simplified, 2-tiered scoring system will have utility in clinical deci-
sion-making and in defining patients eligible for clinical trials.286
LIPOPOLYSACCHARIDE BINDING PROTEIN PROMOTER VARIANTS IN-
FLUENCE THE RISK FOR GRAM-NEGATIVE BACTEREMIA AND MORTAL-
ITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Chien, J.W., Boeckh, M., Hansen, J.A., Clark, J.G. Fred Hutchinson
Cancer Research Center, Seattle, WA.
Lipopolysaccharide binding protein (LBP) function is dependent
upon circulating LBP levels. Disturbance of LBP transcription reg-
ulation may influence the risk for clinical events. We comprehen-
sively assessed the LBP sequence and identified three haplotype
tagging single nucleotide polymorphisms (SNPs) for our studies.
Using a nested case control design, we assessed whether genetic var-
iation in the LBP gene influences the risk for Gram-negative (GN)
bacteremia after allogeneic hematopoietic cell transplantation
(HCT), then confirmed the associations by prospectively assessing
association with an intermediate phenotype (circulating LBP levels)
and a secondary clinical phenotype (mortality). Presence of the SNP
6878 C allele among patients was associated with a two-fold higher
risk for GN bacteremia (odds ratio 2.22, p5 0.001). SNP 6878 was
in strong linkage disequilibrium with three SNPs in the LBP pro-
moter, one of which was SNP 6878 (r25 0.8), located in a promoter
CAAT box. The SNP 1683 C allele was associated with higher me-
dian circulating LBP levels (TT 10.86 6 0.68 mg/ml; TC 13.86 6
1.51 mg/ml; CC 20.66 6 5.89 mg/ml; p 5 0.002) and a three-fold
increase in mortality risk (hazard ratio 3.30, p 5 0.001). These
data suggest that genetic variation in the LBP promoter variation
likely influences the risk for developing GN bacteremia and death
after HCT.287
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR CHEMORADIO-
THERAPY-RELATED MYELODYSPLASTIC SYNDROME AND ACUTE LEU-
KEMIA: A SINGLE-CENTER ANALYSIS OF 47 PATIENTS
Yokoyama, H., Fukuda, T., Kobayashi, Y., Kim, S.-W., Maruyama, D.,
Mori, S.-I., Watanabe, T., Tanosaki, R., Tajima, K., Tobinai, K.,
Takaue, Y. National Cancer Center Hospital, Tokyo, Japan.
Purpose: To examine the value of allogeneic HCT in the treat-
ment of therapy-related myelodysplastic syndrome/acute leukemia
(t-MDS/t-AL) which develops after previous exposure to chemo-
therapy (CT) or radiotherapy. Patients and Methods: We retro-
spectively analyzed the data of 47 patients who were treated at
our institution between 1996 and 2007. The primary diseases in-
cluded malignant lymphoma (n 5 17), breast cancer (n 5 13) and
other solid tumors (n5 17). The median interval between the diag-
nosis of the primary disease and the onset of t-MDS/t-AL was 3.9
years (range, 0.6–18.7). Twenty-five patients had AML, 5 ALL, 1
biphenotypic acute leukemia, and 16 MDS. Results: Thirty-three
patients received disease-adapted CT, with a response rate of
73%, while 14 patients were elected to receive no interventions
due to an indolent clinical course such as MDS-RA (n 5 13).
With a median follow-up of surviving patients of 1.9 years (range,
0.05–10.5) after the diagnosis of t-MDS/t-AL, the 3-year OS for
all patients was 55%. Twenty-seven patients (median age, 47 years:
range, 3–63) underwent allogeneic HCT from related (n 5 12) or
unrelated (n 5 15) donors after myeloablative (n 5 18) or re-
duced-intensity (n 5 9) conditioning regimens. The sources of
stem cells were BM in 15 patients, PBSC in 10, and CB in 2. At
the time of HCT, 18 t-MDS/t-AL were in CR, 1 was in non-CR,
and 8 had untreated t-MDS. Twenty patients (43%) did not un-
dergo HCT due to various reasons, including age older than 65
years (n 5 11), indolent clinical course (n 5 4), progression of the
primary disease (n 5 4) or t-AL (n 5 3), and patient refusal (n 5
2). The 3-year OS was significantly better in patients who received
HCT than in those who did not (71% vs 31%; P 5 0.018). TRM
after HCT was 15%. The 3-year OS was better in those who
achieved CR after initial therapy for t-MDS/t-AL than in those
who did not (74% vs 30%; P 5 0.002). A multivariate analysis re-
vealed that HCT was associated with a significantly better OS,
even after adjusting for age and other significant prognostic factors
including achievement of CR in t-MDS/AL, cytogenetic risk group,
and an interval between the diagnosis of primary disease and t-
MDS/t-AL of longer than 3 years.Conclusion:Although this study
is contaminated by a selection bias, it still appears that HCT was an
effective therapeutic option for patients with t-MDS/t-AL, espe-
cially when patients were in CR.These results support a prospective
study to examine the value of upfront HCT.288
HEALTHY ALLOGENEIC RELATED DONORS OF PERIPHERAL HAEMATO-
POIETIC PROGENITORS: A LONG-TERM PROSPECTIVE STUDY
Tassi, C.1, Arpinati, M.2, Giudice, V.1, Bontadini, A.1. 1Sant’Orsola-
Malpighi Policlinic, Bologna, Italy; 2Sant’Orsola-Malpighi Policlinic,
Bologna, Italy.
One hundred and thirty six healthy donors who underwent
aphaeresis collections after G-CSF stimulation have been included
in a surveillance protocol for a provisional period of ten years. Once
a year, they are required to send aWBC, Hb and platelets count re-
port and clinical information to our Service. To date, the mean ob-
servation time is 46(4–120) months. Fifty out of the 136 donors
show a follow-up longer than 60 months. As previously described
(1), at day 114 after G-CSF administration, a moderate neutrope-
nia or lymphocytopenia, have been documented in 32 and 20 sub-
jects, respectively. Moreover, a mild thrombocytopenia has been
diagnosed during the G-CSF administration in 52 donors. After
a five years period of observation, a persistent, slight reduction of
circulating neutrophils or lymphocytes has been detectable in 5/
32 or 5/20 donors, without clinical relevance. As regards clinical
data, 1 case of MGUS, Insipid Diabetes, Autoimmune Thyroiditis,
Multiple Sclerosis, Intestinal Multiple Polyps and Allergy to certain
food, were the main diseases reported by six donors. Four donors
